MOUNTAIN VIEW, Calif., May 18 /PRNewswire-FirstCall/ -- IRIDEX Corporation today reported that it plans to request a hearing before the Nasdaq Listing Qualifications Panel following the receipt of the expected Nasdaq Staff Determination notice stating that the Company is not in compliance with Nasdaq Marketplace Rule 4310(c)(14). This notice was received because the Company was not timely in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2007, (the “Quarterly Report on Form 10-Q”).
The required Nasdaq Staff Determination notice indicated that the Company’s securities will be delisted from the Nasdaq Global Market unless IRIDEX requests a hearing before a Nasdaq Listing Qualifications Panel (the “Panel”). Accordingly, the Company is announcing today that it is requesting such hearing before the Panel to review the Nasdaq Staff Determination notice. Pending a decision by the Panel, IRIDEX’ common stock will remain listed on the Nasdaq Stock Market. However, there can be no assurance that the Panel will grant the Company’s request for continued listing.
As previously announced, the Company is still obtaining financial information related to the Company’s acquisition of the aesthetics business of Laserscope, a California corporation, a wholly owned subsidiary of American Medical Systems, Inc., a Delaware corporation, which was completed on January 16, 2007. The information is necessary to allow the Company to properly account for the acquisition and to make the appropriate financial statement disclosures, including providing pro forma financial information. The Company previously disclosed in its filing on Form 12b-25 dated May 16, 2007, that it would be unable to file its Quarterly Report on Form 10-Q until it obtains and processes this information. The Company will make every effort to file its Quarterly Report on Form 10-Q as soon as practicable after it receives the necessary information.
About IRIDEX
IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin diseases in dermatology markets (also referred to as aesthetics). IRIDEX products are sold in the United States through a direct sales force and internationally through a network of 77 independent distributors into 107 countries. For further information, visit the Company’s website at http://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company’s plans to request a hearing before a Nasdaq Listing Qualifications Panel, whether the Nasdaq Listing Qualifications Panel will grant the Company’s request for continued listing, the Audit Committee’s review and analysis, and the filing of our Quarterly Report on Form 10-Q. Such forward-looking statements are based on current expectations, estimates and projections, management’s beliefs, and certain assumptions made by the Company’s management, and there can be no assurance concerning the outcome of the hearing request, the Audit Committee’s review and analysis or the filing of our Quarterly Report on Form 10-Q. Actual results may differ materially. Additional risks and uncertainties to which the Company is subject may include, but may not necessarily be limited to, the amount of orders that the Company receives and ships, dependence on international sales and the Company’s network of independent distributors, the risks associated with bringing new products to market, and the results of clinical trials and competition in our markets, as well as the risks associated with a competitive market for management talent and the risks inherent with identifying, negotiating and integrating strategic acquisitions of complementary businesses, products or technologies. Please see a detailed description of these risks contained in our Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ended December 30, 2006 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
IRIDEX Corporation
CONTACT: Meryl Rains, Chief Financial Officer of IRIDEX Corporation,+1-650-940-4700
Web site: http://www.iridex.com/
